SLDB - ソリッド・バイオサイエンシズ （Solid Biosciences Inc.） ソリッド・バイオサイエンシズSLDBのチャート
SLDBの企業情報
| symbol | SLDB |
|---|---|
| 会社名 | Solid Biosciences Inc （ソリッド・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ソリッド・バイオサイエンス(Solid Biosciences Inc.)（旧名：Solid Biosciences、LLC）はライフサイエンス企業である。同社はデュシェンヌ型筋ジストロフィー（DMD）の治療法の開発に注力する。同社はDMDを対象とした遺伝子治療、疾患修正療法、補助デバイスを開発する。矯正療法プラットフォームはDMD用遺伝子治療候補の開発に従事する。リードプログラムであるSGT-001はジストロフィン遺伝子の機能性バージョンの全身送達を可能にすることに焦点を当てたアデノ随伴ウイルス（AAV）マイクロジストロフィン遺伝子治療の候補者である。同社はDMD関連二次的障害を管理するのに役立つ小分子および生物学的候補を検査する。同社はDMD患者のウェアラブルサポートを開発中である。補助装置のハードウェアは力発生アクチュエータ（またはモータ）、電気制御クラッチ、およびFlex Gripと呼ばれるハーネス技術の3つの技術で構成される。 ソリッド・バイオサイエンシズは米国のライフサイエンス企業。米国における筋ジストロフィ―の遺伝子治療の特定と開発に従事。遺伝子導入の主力候補には、患者の筋肉に機能性ジストロフィンタンパク質の発現を回復させるSGT-001があり、アデノ随伴ウイルス(AAV)ベクタ―による遺伝子治療として臨床試験を手掛ける。本社所在地はマサチュ―セッツ州ケンブリッジ。 |
| 本社所在地 | 141 Portland Street Fifth Floor Cambridge MA 02139 USA |
| 代表者氏名 | Andrey J. Zarur アンドレイ・J・ザール |
| 代表者役職名 | Chairman of the Board Co-Founder |
| 電話番号 | +1 617-337-4682 |
| 設立年月日 | 41334 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 60人 |
| url | www.solidbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sldb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -62.13500 |
| 終値（lastsale） | 37.35 |
| 時価総額（marketcap） | 1323402381 |
| 時価総額 | 時価総額（百万ドル） 1212.144 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 149.385 |
| 当期純利益 | 当期純利益（百万ドル） -61.84900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Solid Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased from $11.3M to $33.9M. Higher net loss reflects Research and development increase of 41% to $23.8M (expense) General and administrative increase of 51% to $8.2M (expense) Stock-based Compensation in R&D increase from $504K to $1.7M (expense). |
SLDBのテクニカル分析
SLDBのニュース
Solid Biosciences to Participate in Chardan''s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit 2023/04/21 12:00:00 Benzinga
CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB ), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Solid management will participate in a fireside chat at Chardan''s 7 th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023 at 2:00 PM ET. A live webcast of the fireside chat will be available on the Events page of the Investors section of the … Full story available on Benzinga.com
Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference 2023/04/13 12:00:00 GlobeNewswire
CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 22 nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 8:00 AM ET.
Solid Biosciences reports Q4 results 2023/03/23 12:44:04 Seeking Alpha
Solid Biosciences press release (SLDB): Q4 Net loss of $15.2MSolid had $213.7 million in cash, cash equivalents, and available-for-sale securities as of December 31, 2022, compared…
Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results 2023/03/23 12:00:00 GlobeNewswire
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement -
Solid Biosciences to Present at Barclays Global Healthcare Conference 2023/03/07 13:00:00 GlobeNewswire
CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023, at 3:35 PM ET.
Solid Biosciences to Present at SVB Securities Global Biopharma Conference 2023/02/08 13:00:00 GlobeNewswire
CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 1:40 pm ET.
Solid Biosciences, Phlox team up to develop precision drugs for heart diseases 2023/01/11 13:58:34 Seeking Alpha
Solid Biosciences (SLDB) and Phlox Therapeutics entered a strategic collaboration for developing precision medicines for genetic cardiac diseases.The research collaboration will target…
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases 2023/01/11 13:00:00 GlobeNewswire
CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a strategic collaboration focused on genetic cardiac diseases. The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM) for which there is currently a significant unmet need for effective treatments.
Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer 2023/01/09 21:26:00 GlobeNewswire
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed Chief Financial Officer and Treasurer, Kevin Tan. The grant was approved by a majority of the independent directors of the Company on January 6, 2023, as an inducement material to Mr. Tan’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Kevin Tan is the new finance chief at Solid Biosciences 2023/01/09 13:20:56 Seeking Alpha
Solid Biosciences (SLDB) appoints a seasoned industry professional, Kevin Tan, CFA, , as CFO.Most recently he served as CFO at Selecta Biosciences.
Solid Biosciences, Phlox team up to develop precision drugs for heart diseases 2023/01/11 13:58:34 Seeking Alpha
Solid Biosciences (SLDB) and Phlox Therapeutics entered a strategic collaboration for developing precision medicines for genetic cardiac diseases.The research collaboration will target…
Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases 2023/01/11 13:00:00 GlobeNewswire
CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and Phlox Therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a strategic collaboration focused on genetic cardiac diseases. The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM) for which there is currently a significant unmet need for effective treatments.
Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer 2023/01/09 21:26:00 GlobeNewswire
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to its newly appointed Chief Financial Officer and Treasurer, Kevin Tan. The grant was approved by a majority of the independent directors of the Company on January 6, 2023, as an inducement material to Mr. Tan’s entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Kevin Tan is the new finance chief at Solid Biosciences 2023/01/09 13:20:56 Seeking Alpha
Solid Biosciences (SLDB) appoints a seasoned industry professional, Kevin Tan, CFA, , as CFO.Most recently he served as CFO at Selecta Biosciences.
Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer 2023/01/09 13:01:00 GlobeNewswire
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the appointment of Kevin Tan, CFA, a seasoned industry professional, as Chief Financial Officer.